Incyte news
The WiseView Research desk's stories that name Incyte, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The INCY page →
- HeadlineIncyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
- HeadlineIncyte Highlights Promising Early Data for '890 and '734 in GI Cancers
- HeadlineIncyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
- HeadlineIncyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
- HeadlineIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
- HeadlineIncyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
- HeadlinePrelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
- HeadlineAnalysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for
- HeadlineIncyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
- HeadlineIncyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community
- CongressRo Khanna bought $1,001 - $15,000 of INCY
- HeadlineIncyte to Report Third Quarter Financial Results
- HeadlineINCY or TECH: Which Is the Better Value Stock Right Now?
- CongressRob Bresnahan sold $1,001 - $15,000 of INCY
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.